Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
nutritional and metabolic diseases | D009750 |
Brand Name | Status | Last Update |
---|---|---|
011010 niacinamide 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
011013 niacinamide 4% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
011020 niacinamide 4% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
011021 niacinamide 4% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
011054 niacinamide 4% / spironolactone 5% | unapproved drug other | 2020-07-02 |
011218 niacinamide 2% / spironolactone 5% / tretinoin 0.025% | unapproved drug other | 2020-07-02 |
011220 niacinamide 2% / spironolactone 5% / tretinoin 0.05% | unapproved drug other | 2020-07-02 |
011312 niacinamide 4% / tazarotene 0.05% | unapproved drug other | 2020-07-02 |
011503 dapsone 6% / niacinamide 2% / spironolactone 5% | unapproved drug other | 2020-07-02 |
011504 dapsone 8.5% / niacinamide 4% | unapproved drug other | 2020-07-02 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hypercholesterolemia | — | D006937 | — |
hypertriglyceridemia | EFO_0004211 | D015228 | — |
peripheral vascular diseases | EFO_0003875 | D016491 | I73.9 |
pellagra | — | D010383 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dyslipidemias | D050171 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypercholesterolemia | D006937 | — | — | — | 1 | 2 | — | — | 3 |
Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 1 | 2 | — | — | 3 |
Laryngeal neoplasms | D007822 | EFO_0003817 | C32 | — | — | 1 | — | — | 1 |
Hypopharyngeal neoplasms | D007012 | — | C13 | — | — | 1 | — | — | 1 |
Laryngeal diseases | D007818 | — | J38.7 | — | — | 1 | — | — | 1 |
Homozygous familial hypercholesterolemia | D000090542 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Niacin |
INN | nicotinic acid |
Description | Nicotinic acid is a pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group. It has a role as an antidote, an antilipemic drug, a vasodilator agent, a metabolite, an EC 3.5.1.19 (nicotinamidase) inhibitor, an Escherichia coli metabolite, a mouse metabolite, a human urinary metabolite and a plant metabolite. It is a vitamin B3, a pyridinemonocarboxylic acid and a pyridine alkaloid. It is a conjugate acid of a nicotinate. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1cccnc1 |
PDB | — |
CAS-ID | 59-67-6 |
RxCUI | — |
ChEMBL ID | CHEMBL573 |
ChEBI ID | 15940 |
PubChem CID | 938 |
DrugBank | DB00627 |
UNII ID | 2679MF687A (ChemIDplus, GSRS) |